Envista Holdings Co. (NYSE:NVST) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA lessened its stake in Envista Holdings Co. (NYSE:NVST) by 5.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 549,840 shares of the company’s stock after selling 33,235 shares during the period. Leeward Investments LLC MA’s holdings in Envista were worth $10,606,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its position in Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock valued at $69,749,000 after buying an additional 642,401 shares during the period. Diamond Hill Capital Management Inc. boosted its position in Envista by 8.1% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company’s stock valued at $26,394,000 after buying an additional 100,360 shares during the period. Harbor Capital Advisors Inc. boosted its position in Envista by 138.5% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 404,589 shares of the company’s stock valued at $7,995,000 after buying an additional 234,941 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Envista in the 4th quarter valued at approximately $53,000. Finally, Lecap Asset Management Ltd. purchased a new position in Envista in the 4th quarter valued at approximately $281,000.

Envista Price Performance

Shares of NYSE:NVST opened at $20.91 on Friday. The company’s fifty day moving average price is $20.11 and its 200 day moving average price is $19.52. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $23.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The firm has a market capitalization of $3.60 billion, a P/E ratio of -3.22, a P/E/G ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, sell-side analysts predict that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVST has been the subject of several recent research reports. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Wells Fargo & Company lifted their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Jefferies Financial Group lifted their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Morgan Stanley lifted their price objective on shares of Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Finally, Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $20.21.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.